Sort
48,018 grants matching “immunotherapy”
A Novel Adenoviral-Permissive, Immunocompetent Hamster Model to Evaluate Oncolytic Adenoviral Therapy for Glioblastoma
$454,473Frederick F Lang · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Understanding Metabolic and Epigenetic Crossâ talk in Potent Antiâ tumor T cells
$454,472Shikhar Mehrotra · Medical University Of South Carolina · R01 · FY2023 · CA
Understanding Metabolic and Epigenetic Crossâ talk in Potent Antiâ tumor T cells
$454,467Shikhar Mehrotra · Medical University Of South Carolina · R01 · FY2022 · CA
Core D: Pathology and BioImaging
$454,463Carl D Morrison · Roswell Park Cancer Institute Corp · P01 · FY2023 · CA
Translational and Clinical Trial Correlates Core
$454,395Claudia Marcela Diaz-Montero · Cleveland Clinic Lerner Com-Cwru · U54 · FY2022 · CA
Research Training in Hematology
$454,314John Patrick Sheehan · University Of Wisconsin-Madison · T32 · FY2022 · HL
Targeted Gene Delivery and Human Dendritic Cell Maturation Through a Novel Hybrid Biological-Biomaterial Vector System
$454,261Blaine A. Pfeifer · State University Of New York At Buffalo · R01 · FY2024 · CA
Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma
$454,247David McDermott · Beth Israel Deaconess Medical Center · R01 · FY2022 · CA
BRAIN TUMORS--IMMUNOLOGICAL AND BIOLOGICAL STUDIES
$454,245Duke University · R37 · FY2000 · CA
Molecular basis of glycan recognition by T and B cells
$454,191Luc Teyton · Scripps Research Institute, The · P01 · FY2024 · AI
Molecular basis of glycan recognition by T and B cells
$454,191Luc Teyton · Scripps Research Institute, The · P01 · FY2023 · AI
Developing newly combined therapeutic strategies for mature B cell lymphoma
$454,144Jing Hong Wang · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA
Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer
$454,144Andrew J Armstrong · Duke University · R01 · FY2022 · CA
Development of mAb immunotherapy for genetically modified plague
$454,113James B Bliska · Columbia University Health Sciences · U54 · FY2010 · AI
Amyloid-Lowering Small Molecule AB-Binding Agents in AD
$454,087William E Klunk · University Of Pittsburgh At Pittsburgh · U01 · FY2008 · AG
Project 2: Spatial Architecture of Tumor-Mediated Immunosuppression
$454,052Garry P Nolan · Stanford University · U54 · FY2019 · CA
Project 3: Adaptive immunity to MCPyV in Merkel cell carcinoma
$454,020David M Koelle · University Of Washington · P01 · FY2022 · CA
Paraneoplastic Disorders of the CNS: Autoantigen Profiling
$454,000Josep Dalmau · University Of Pennsylvania · R01 · FY2012 · NS
A Comprehensive 5K Plus Glycan Microarray
$453,966Jian Zhang · Z Biotech, Llc · R44 · FY2023 · GM
A Wireless Multi-function Microscope for Lifetime Imaging of the Brain Tumor Vasculome
$453,962Arvind P Pathak · Johns Hopkins University · R01 · FY2020 · CA
Project 3: Understanding genomic and external drivers of response-predictive inflammatory states underlying differences in clinical outcomes in patients with breast cancer
$453,954Elad Ziv · University Of California, San Francisco · U54 · FY2025 · CA
Mechanisms of cell death in cutaneous melanoma
$453,931Andrew E Aplin · Thomas Jefferson University · R01 · FY2024 · CA
Repurposing Glucosylceramide Synthase to Promote Mitochondrial Lethality and Potentiate an Anti-Tumor Immune Response in Triple-Negative Breast Cancer
$453,927Johannes F Fahrmann · University Of Tx Md Anderson Can Ctr · R37 · FY2024 · CA
Clinical treatment of advanced Merkel cell carcinoma
$453,913Isaac Brownell · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2023 · AR
Trial Using Epsilon Aminocaproic Acid Therapy in Thrombocytopenia - DCC
$453,893Scott S Emerson · University Of Washington · U01 · FY2015 · HL